Tag: 300-400

Shankar, G.; Borkar, Roshan M.; Udutha, Suresh; Kanakaraju, M.; Charan, G. Sai; Misra, S.; Srinivas, R. published an article in 2019, the title of the article was Identification and structural characterization of the stress degradation products of omeprazole using Q-TOF-LC-ESI-MS/MS and NMR experiments: evaluation of the toxicity of the degradation products.Quality Control of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole And the article contains the following content:

Omeprazole (OMP), a prototype proton pump inhibitor used for the treatment of peptic ulcers and gastroesophageal reflux disease (GERD), was subjected to forced degradation studies as per ICH guidelines Q1A (R2). The drug undergoes degradation under acid, base, neutral hydrolysis and oxidative degradation conditions and forms a total of sixteen degradation products, which were characterized by LC-MS/MS experiments and accurate mass measurements. Oxidative degradation products (OMP-15 and OMP-16) were synthesized and confirmed by various NMR experiments The cytotoxic effects of OMP-15 and OMP-16 were tested on normal human cells HEK 293 and NIH3T3 by MTT assay. Based on the cytotoxicity results, compared to the standard OMP, both OMP-15 and OMP-16 were found to have relatively weaker toxic effects towards normal cells. Further, the in silico toxicity of OMP and its degradation products (OMP-1 to OMP-16) was assessed by the ProTox-II prediction tool. OMP and OMP-8 are predicted to have carcinogenicity, OMP-7 to have hepatotoxicity and OMP-2, OMP-3, OMP-9, OMP-11, OMP-14 and OMP-16 to have immune system toxicity with a high confidence score. The drug, OMP-1, OMP-6, OMP-7, OMP-8, OMP-13 and OMP-15 are predicted to combine with the aryl hydrocarbon receptor (AhR) with a high probability score. Addnl., two different targets, amine oxidase A and prostaglandin G/H synthase 1, are predicted as toxicity targets for OMP, OMP-1, OMP-6, OMP-8, OMP-13, OMP-15 and OMP-16 with probable binding. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Quality Control of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole

The Article related to omeprazole stress degradation product nmr lc ms, Pharmaceuticals: General and other aspects.Quality Control of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On July 1, 2006, Kurosu, Michio; Mowers, Williams A. published an article.Recommanded Product: 901770-40-9 The title of the article was Small-molecule microarrays: Development of novel linkers and an efficient detection method for bound proteins. And the article contained the following:

Novel isocyanate and diazoketone linkers possessing polyoxypropylenediamine as a spacer for small-mol. microarray are developed. White light interferometry is introduced to detect bound proteins on the glass slides without using chem. modified proteins. The experimental process involved the reaction of N-(4-Hydroxyphenyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide(cas: 901770-40-9).Recommanded Product: 901770-40-9

The Article related to microarray isocyanate diazoketone linker bound protein, Pharmacology: Methods and other aspects.Recommanded Product: 901770-40-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On October 15, 2008, Carlton, David L.; Collin-Smith, Lissa J.; Daniels, Alejandro J.; Deaton, David N.; Goetz, Aaron S.; Laudeman, Christopher P.; Littleton, Thomas R.; Musso, David L.; Morgan, Ronda J. Ott; Szewczyk, Jerzy R.; Zhang, Cunyu published an article.Electric Literature of 73590-85-9 The title of the article was Discovery of small molecule agonists for the bombesin receptor subtype 3 (BRS-3) based on an omeprazole lead. And the article contained the following:

Starting from a weak omeprazole screening hit, replacement of the pyridine with a 1,3-benzodioxole moiety, modification of the thioether linkage, and substitution of the benzimidazole pharmacophore led to the discovery of nanomolar BRS-3 agonists. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Electric Literature of 73590-85-9

The Article related to bombesin receptor brs3 agonist preparation structure activity, Pharmacology: Structure-Activity and other aspects.Electric Literature of 73590-85-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On July 31, 2013, Shirasaka, Yoshiyuki; Sager, Jennifer E.; Lutz, Justin D.; Davis, Connie; Isoherranen, Nina published an article.SDS of cas: 73590-85-9 The title of the article was Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. And the article contained the following:

The aim of this study was to evaluate the contribution of metabolites to drug-drug interactions (DDI) using the inhibition of CYP2C19 and CYP3A4 by omeprazole and its metabolites as a model. Of the metabolites identified in vivo, 5-hydroxyomeprazole, 5′-O-desmethylomeprazole, omeprazole sulfone, and carboxyomeprazole had a metabolite to parent area under the plasma concentration-time curve (AUCm/AUCp) ratio ≥ 0.25 when either total or unbound concentrations were measured after a single 20-mg dose of omeprazole in a cocktail. All of the metabolites inhibited CYP2C19 and CYP3A4 reversibly. In addition omeprazole, omeprazole sulfone, and 5′-O-desmethylomeprazole were time dependent inhibitors (TDI) of CYP2C19, whereas omeprazole and 5′-O-desmethylomeprazole were found to be TDIs of CYP3A4. The in vitro inhibition constants and in vivo plasma concentrations were used to evaluate whether characterization of the metabolites affected DDI risk assessment. Identifying omeprazole as a TDI of both CYP2C19 and CYP3A4 was the most important factor in DDI risk assessment. Consideration of reversible inhibition by omeprazole and its metabolites would not identify DDI risk with CYP3A4, and with CYP2C19, reversible inhibition values would only identify DDI risk if the metabolites were included in the assessment. On the basis of inactivation data, CYP2C19 and CYP3A4 inhibition by omeprazole would be sufficient to identify risk, but metabolites were predicted to contribute 30-63% to the in vivo hepatic interactions. Therefore, consideration of metabolites may be important in quant. predictions of in vivo DDIs. The results of this study show that, although metabolites contribute to in vivo DDIs, their relative abundance in circulation or logP values do not predict their contribution to in vivo DDI risk. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).SDS of cas: 73590-85-9

The Article related to omeprazole metabolism intestine liver cyp2c19 cyp3a4 protein, Pharmacology: Structure-Activity and other aspects.SDS of cas: 73590-85-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On September 30, 2007, El Alaoui, Abdessamad; Schmidt, Frederic; Amessou, Mohamed; Sarr, Marianne; Decaudin, Didier; Florent, Jean-Claude; Johannes, Ludger published an article.Recommanded Product: 901770-40-9 The title of the article was Shiga toxin-mediated retrograde delivery of a topoisomerase I inhibitor prodrug. And the article contained the following:

A retrograde strategy: An innovative cancer-cell delivery concept exploits the naturally evolved characteristics of the Shiga toxin B-subunit (STxB) for the intracellular activation of a newly synthesized prodrug at the level of the biosynthetic/secretory pathway. Retrograde prodrug targeting allows its slow release, which should sustain the presence of the active principle in dividing tumor cells. The experimental process involved the reaction of N-(4-Hydroxyphenyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide(cas: 901770-40-9).Recommanded Product: 901770-40-9

The Article related to shiga toxin retrograde delivery topoisomerase i inhibitor prodrug, Pharmaceuticals: Pharmaceutics and other aspects.Recommanded Product: 901770-40-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Nalwade, Santaji Uttam; Reddy, Vangala Ranga; Rao, Dantu Durga; Morisetti, Nagendra kumar published an article in 2011, the title of the article was A validated stability indicating ultra performance liquid chromatographic method for determination of impurities in Esomeprazole magnesium gastro resistant tablets.Safety of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole And the article contains the following content:

A novel gradient reversed-phase ultra performance liquid chromatog. method has been developed for quant. determination of Esomeprazole magnesium and its seven impurities in pharmaceutical dosage forms. Chromatog. separation has been achieved on an Acquity BEH C18, 50 mm × 2.1 mm, 1.7 μm with buffered mobile phase consisting solvent A (0.04 M (M) glycine (pH 9.0) buffer) and solvent B (mixture of acetonitrile and Milli-Q water in the ratio 90: 10 (volume/volume); resp.) delivered at flow rate of 0.21 mL min-1 and the detection wavelength 305 nm. Resolution of Esomeprazole magnesium and all the seven potential impurities has been achieved greater than 2.0 for all pairs of compounds The drug was subjected to the stress conditions of oxidative, acid, base, hydrolytic, thermal and photolytic degradation Esomeprazole magnesium was found to degrade significantly in oxidative and acid hydrolysis stress conditions and stable in base, hydrolytic and photolytic degradation conditions. The degradation products were well resolved from main peak and its impurities, thus proved the stability indicating power of the method. The stress samples were assayed against a reference standard and the mass balance was found to be close to 99.1%. So this method was also suitable for Assay determination of Esomeprazole magnesium in pharmaceutical dosage forms. The developed method was validated as per ICH guidelines with respect to specificity, linearity, limit of detection, limit of quantification, accuracy, precision and robustness. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Safety of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole

The Article related to liquid chromatog impurity esomeprazole magnesium tablet stress, Pharmaceuticals: Pharmaceutics and other aspects.Safety of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On November 21, 2017, Moutzouri, Pinelopi; Kiraly, Peter; Phillips, Andrew R.; Coombes, Steven R.; Nilsson, Mathias; Morris, Gareth A. published an article.SDS of cas: 73590-85-9 The title of the article was 13C Satellite-Free 1H NMR Spectra. And the article contained the following:

A new NMR experiment (Destruction of Interfering Satellites by Perfect Echo Low-pass filtration, DISPEL) is introduced that facilitates the anal. of low-level components in high dynamic range mixtures by suppressing one-bond 13C satellite signals in 1H spectra. Since the natural abundance of 13C is around 1.1%, these satellites appear at 0.54% of the intensity of a parent peak, mimicking and often masking impurity signals. The new experiment suppresses one-bond 13C satellite signals, with high efficiency, at negligible cost in signal-to-noise ratio, and over a wide range of one-bond coupling constants, without the need for broadband 13C decoupling. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).SDS of cas: 73590-85-9

The Article related to dispel nmr one bond satellite signal suppression, Magnetic Phenomena: Nuclear Resonances and other aspects.SDS of cas: 73590-85-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On May 31, 2019, Makino, Kosho; Hasegawa, Yumi; Inoue, Takahide; Araki, Koji; Tabata, Hidetsugu; Oshitari, Tetsuta; Ito, Kiyomi; Natsugari, Hideaki; Takahashi, Hideyo published an article.Safety of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole The title of the article was Chemoselective Demethylation of Methoxypyridine. And the article contained the following:

A chemoselective demethylation method for various methoxypyridine derivatives I (R = 3-OMe, 4-CH2=CHCH2O, 4-C6H5CH2O, etc.; X = H, 5-Cl, 4-Me, etc.; Y = CH, N) has been developed. Treatment of 4-methoxypyridine with L-selectride in THF for 2 h at reflux temperature afforded 4-hydroxypyridine in good yield; and no reaction to anisole is occurred. The utility of this method was demonstrated by the efficient synthesis of the metabolic substances of the antiulcer agent omeprazole. Chemoselective demethylation at the site of 3,5-dimethyl-4-methoxypyridine in the presence of 4-methoxybenzimidazole was achieved. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Safety of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole

The Article related to hydroxypyridine preparation chemoselective, alkoxy pyridine demethylation, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Safety of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On January 25, 2016, Jadhav, Sushant Bhimrao; Kumar, C. Kiran; Bandichhor, Rakeshwar; Bhosale, P. N. published an article.Electric Literature of 73590-85-9 The title of the article was Development of RP UPLC-TOF/MS, stability indicating method for omeprazole and its related substances by applying two level factorial design; and identification and synthesis of non-pharmacopoeial impurities. And the article contained the following:

A new UPLC-TOF/MS compatible, reverse phase-stability indicating method was developed for determination of Omeprazole (OMP) and its related substances in pharmaceutical dosage forms by implementing Design of Experiment (DoE) i.e. two level full factorial Design (23 + 3 center points = 11 experiments) to understand the Critical Method Parameters (CMP) and its relation with Critical Method Attribute (CMA); to ensure robustness of the method. The separation of eleven specified impurities including conversion product of OMP related compound F (13) and G (14) i.e. Impurity-I (1), OMP related compound-I (11) and OMP 4-chloro analog (12) was achieved in a single method on Acquity BEH shield RP18 100 × 2.1 mm, 1.7 μm column, with inlet filter (0.2 μm) using gradient elution and detector wavelength at 305 nm and validated in accordance with ICH guidelines and found to be accurate, precise, reproducible, robust and specific. The drug was found to degrade extensively in heat, humidity and acidic conditions and forms unknown degradation products during stability studies. The same method was used for LC-MS anal. to identify m/z and fragmentation of maximum unknown impurities (Non-Pharmacopoeial) i.e. Impurity-I (1), Impurity-III (3), Impurity-V (5) and Impurity-VIII (9) formed during stability studies. Based on the results, degradation pathway for the drug has been proposed and synthesis of identified impurities i.e. impurities (Impurity-I (1), Impurity-III (3), Impurity-V (5) and Impurity-VIII (9)) are discussed in detail to ensure in-depth understanding of OMP and its related impurities and optimum performance during lifetime of the product. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Electric Literature of 73590-85-9

The Article related to uplc tof ms omeprazole related substances factorial design impurity, design of experiments (doe), development, full factorial design, omeprazole, uplc-tof/ms, validation, Pharmaceutical Analysis: Synthetic Organic Compounds and other aspects.Electric Literature of 73590-85-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On June 30, 2013, Seshadri, Raja Kumar; Raghavaraju, Thummala Veera; Chakravarthy, Ivon Elisha published an article.Category: imidazoles-derivatives The title of the article was A single gradient stability-indicating reversed-phase LC method for the estimation of impurities in omeprazole and domperidone capsules. And the article contained the following:

A gradient reversed-phase liquid chromatog. (RP-LC) method was developed for the quant. estimation of impurities in the pharmaceutical dosage form of Omeprazole and Domperidone capsules. The developed method is a stability-indicating test method for the estimation of impurities generated during the formulation and storage of Omeprazole and Domperidone capsules. The chromatog. separation was achieved on a column packed with octadecyl silane, having a column length of 250 mm and diameter of 4.6 mm with a particle size of 5 μm, and by following a gradient program using a combination of a monobasic potassium phosphate buffer (0.05M) and acetonitrile. Since the spectral properties were similar, both compounds’ individual impurities were estimated at 285 nm. Forced degradation studies were performed on Omeprazole pellets (enteric coated) and Domperidone pellets (SR coated) encapsulated in size “1” hard gelatin capsules. Omeprazole and Domperidone were degraded using acid hydrolysis (0.1 N hydrochloric acid), base (0.1 N sodium hydroxide), oxidation (50% hydrogen peroxide), heat (105 °C), and UV light (254 nm). The established method was validated and found to be linear, accurate, precise, specific, robust, and rugged. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Category: imidazoles-derivatives

The Article related to omeprazole domperidone impurity determination rp hplc capsule degradation, domperidone, forced degradation, method validation, omeprazole, rp-lc, Pharmaceutical Analysis: Synthetic Organic Compounds and other aspects.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem